Zifi Lbx Neo Tablet is a combination antibiotic formulation containing Cefixime (200 mg), Cloxacillin (500 mg), and Lactobacillus (90 million spores), designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits potent bactericidal activity by inhibiting bacterial cell wall synthesis, effective against gram-negative and certain gram-positive pathogens. Cloxacillin, a beta-lactamase resistant penicillin, targets penicillinase-producing Staphylococcus aureus and other susceptible gram-positive bacteria, providing enhanced coverage against resistant strains. The inclusion of Lactobacillus, a probiotic, helps restore and maintain normal gut flora, reducing the risk of antibiotic-associated diarrhea and gastrointestinal disturbances commonly seen with broad-spectrum antibiotic therapy. Zifi Lbx Neo is indicated for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial infections. It is essential to use this medication under medical supervision, with dosage and duration tailored to the severity and type of infection. Patients should inform their healthcare provider of any allergies to beta-lactam antibiotics or history of gastrointestinal disorders prior to initiating therapy. Adverse effects may include gastrointestinal discomfort, hypersensitivity reactions, and rarely, superinfection. Proper adherence to prescribed therapy is critical to prevent resistance development.